^
Association details:
Biomarker:MSI-L/dMMR
Cancer:Penile Cancer
Drug:Tyvyt (sintilimab) (PD1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
Title:

PD-1 inhibitor treatment in a penile cancer patient with MMR/MSI status heterogeneity: A case report

Published date:
11/30/2022
Excerpt:
A 68-year-old patient was hospitalized with bilateral inguinal lymph node metastasis and local penile recurrence after penile cancer surgery. The lesion of the right inguinal lymph node showed a mismatch-repair-deficient (dMMR)/microsatellite instability-low (MSI-L) status. After 3 cycles of sintilimab (a PD1 inhibitor) combined with paclitaxel and cisplatin, the partial response of the tumor was evaluated....Interestingly, after continued treatment with sintilimab combined with gemcitabine, the patient achieved a partial response again.
Secondary therapy:
cisplatin + gemcitabine + paclitaxel
DOI:
10.1080/21645515.2022.2121122